Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a unique class of neurodegenerative disorders characterized by progressive [neurodegeneration](diseases/neurodegeneration), spongiform vacuolation, and typically fatal neurological decline[@prusiner1998]. These diseases affect both humans and animals, representing a fascinating intersection of infectious, sporadic, and genetic etiologies. The central mechanism underlying all prion diseases involves the conformational conversion of the normal cellular [prion protein](/proteins/prion-protein) ([prion protein](/proteins/prion-protein)^C) into an abnormal, disease-associated isoform ([prion protein](/proteins/prion-protein)^Sc), which accumulates in the brain and triggers neurotoxicity[@caughey2003].
The prion concept, initially controversial when proposed by Stanley Prusiner in the 1980s, has since become a paradigm-shifting model in neurodegenerative disease research. Unlike conventional pathogens (viruses, bacteria), prions consist entirely of protein and propagate through template-directed conformational change rather than nucleic acid replication[@prusiner1997]. This discovery earned Prusiner the Nobel Prize in Physiology or Medicine in 1997 and fundamentally altered our understanding of protein misfolding in disease.
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are a unique class of neurodegenerative disorders characterized by progressive [neurodegeneration](diseases/neurodegeneration), spongiform vacuolation, and typically fatal neurological decline[@prusiner1998]. These diseases affect both humans and animals, representing a fascinating intersection of infectious, sporadic, and genetic etiologies. The central mechanism underlying all prion diseases involves the conformational conversion of the normal cellular [prion protein](/proteins/prion-protein) ([prion protein](/proteins/prion-protein)^C) into an abnormal, disease-associated isoform ([prion protein](/proteins/prion-protein)^Sc), which accumulates in the brain and triggers neurotoxicity[@caughey2003].
The prion concept, initially controversial when proposed by Stanley Prusiner in the 1980s, has since become a paradigm-shifting model in neurodegenerative disease research. Unlike conventional pathogens (viruses, bacteria), prions consist entirely of protein and propagate through template-directed conformational change rather than nucleic acid replication[@prusiner1997]. This discovery earned Prusiner the Nobel Prize in Physiology or Medicine in 1997 and fundamentally altered our understanding of protein misfolding in disease.
Human prion diseases are classified into three major categories based on their etiology: sporadic, genetic, and acquired[@collins2004].
Sporadic Creutzfeldt-Jakob Disease (sCJD) represents the most common human prion disease, accounting for approximately 85% of all cases with an annual incidence of about 1-2 per million worldwide[@ladogana2005]. The etiology of sCJD remains unknown, though hypotheses include spontaneous conversion of [prion protein](/proteins/prion-protein)^C to [prion protein](/proteins/prion-protein)^Sc, somatic mutations, or exposure to undetected environmental prions. The disease typically presents in late middle age (average onset 60-65 years) and progresses rapidly to death within months.
Variant Creutzfeldt-Jakob Disease (vCJD) is the human form of bovine spongiform encephalopathy (BSE), acquired through consumption of contaminated beef products[@will1996]. First identified in the United Kingdom in 1996, vCJD differs from sCJD in several important respects: younger age of onset (average 28 years), longer disease duration (12-14 months), and distinctive neuropathological features including prominent [prion protein](/proteins/prion-protein) [amyloid plaques](/mechanisms/amyloid-pathology). The epidemic peaked in the early 2000s with over 200 cases, primarily in the United Kingdom, and has since declined due to effective food safety measures.
Fatal Familial Insomnia (FFI) and Familial Creutzfeldt-Jakob Disease (fCJD) are autosomal dominant genetic prion diseases caused by mutations in the [prion protein](/proteins/prion-protein) gene (PRNP)[@gambetti2003]. FFI is associated with the D178N mutation combined with methionine at position 129, while fCJD is linked to various mutations including E200K, V210I, and P102L. These mutations predispose individuals to spontaneous [prion protein](/proteins/prion-protein)^Sc formation, though disease onset typically occurs in middle to late adulthood.
Kuru was a pioneering disease in prion research, first described in the Fore people of Papua New Guinea and transmitted through ritualistic cannibalism[@collinge2006]. The epidemic provided crucial evidence for the transmissible nature of these disorders and has largely disappeared since the practice ceased in the 1960s.
Iatrogenic [CJD](/diseases/creutzfeldt-jakob) occurs through accidental transmission via medical procedures, including dura mater grafts, corneal transplants, contaminated human growth hormone, and neurosurgical instruments[@brown2000].
Animal prion diseases include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE, "mad cow disease") in cattle, chronic wasting disease (CWD) in cervids (deer, elk, moose), and feline spongiform encephalopathy in cats[@detwiler1997].
The [prion protein](/proteins/prion-protein) ([prion protein](/proteins/prion-protein)) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein expressed predominantly in [neurons](/cell-types/neurons) and glial cells throughout the brain[@caughey2006]. The normal cellular isoform ([prion protein](/proteins/prion-protein)^C) is a monomeric, alpha-helical protein that is proteolytically stable and completely non-toxic. Its physiological function remains incompletely understood, though evidence suggests roles in synaptic plasticity, copper binding, and neuroprotection.
The disease-associated isoform ([prion protein](/proteins/prion-protein)^Sc) differs from [prion protein](/proteins/prion-protein)^C primarily in its secondary and tertiary structure. [prion protein](/proteins/prion-protein)^Sc contains a high beta-sheet content (40-50% versus 10-20% for [prion protein](/proteins/prion-protein)^C), forms amyloid fibrils, and exhibits partial protease resistance[@prusiner2021]. This structural transition is the fundamental event in prion disease pathogenesis.
The precise mechanisms by which [prion protein](/proteins/prion-protein)^Sc accumulation leads to neuronal death remain under investigation. Several non-mutually exclusive hypotheses have been proposed:
Loss of function: [prion protein](/proteins/prion-protein)^Sc formation may deplete functional [prion protein](/proteins/prion-protein)^C, disrupting its normal neuroprotective activities[@mallucci2007]. However, [prion protein](/proteins/prion-protein) knock-out mice do not develop spontaneous [neurodegeneration](diseases/neurodegeneration), suggesting loss of function alone is insufficient.
Gain of toxic function: [prion protein](/proteins/prion-protein)^Sc oligomers and aggregates may directly disrupt neuronal homeostasis through disruption of synaptic function, ion channel dysregulation, and activation of apoptotic pathways[@aguzzi2009].
Endoplasmic reticulum stress: [prion protein](/proteins/prion-protein)^Sc accumulation in the secretory pathway triggers unfolded protein response (UPR) and endoplasmic reticulum stress, leading to cellular dysfunction and death[@hetz2003].
Neuroinflammation: Prion disease is associated with prominent microglial activation and [neuroinflammation](/mechanisms/neuroinflammation), which may both result from and contribute to [neurodegeneration](diseases/neurodegeneration)[@vlgyi2010].
Prion strains are distinct biological variants that cause different disease phenotypes despite being composed of the same [prion protein](/proteins/prion-protein) amino acid sequence[@collinge2001]. Strain differences are encoded in the conformation of the [prion protein](/proteins/prion-protein)^Sc aggregate, which determines incubation period, neuropathology, and species barrier properties. The existence of prion strains provides a molecular basis for the phenotypic diversity observed in human prion diseases.
The clinical presentation of human prion diseases varies somewhat by subtype but shares common features[@appleby2021]. Cognitive decline, typically rapid in progression, is the most common presenting symptom. Patients develop progressive dementia, often accompanied by ataxia (coordination difficulties), myoclonus (involuntary muscle jerks), and visual disturbances. Psychiatric symptoms including depression, anxiety, and personality changes may precede neurological signs.
In variant [CJD](/diseases/creutzfeldt-jakob), psychiatric symptoms are more prominent early in the disease course, with behavioral changes, anxiety, and social withdrawal common initial manifestations. Sleep disturbances, particularly insomnia, are a hallmark of fatal familial insomnia.
Clinical diagnosis relies on a combination of clinical features, characteristic findings on electroencephalography (EEG), and detection of 14-3-3 protein in cerebrospinal fluid[@zerr2004]. The EEG in [CJD](/diseases/creutzfeldt-jakob) typically shows periodic sharp wave complexes, though this finding is not universal. MRI may show characteristic signal changes in the [basal ganglia](/brain-regions/basal-ganglia), cortex, or [thalamus](/brain-regions/thalamus). Definitive diagnosis requires neuropathological examination or detection of [prion protein](/proteins/prion-protein)^Sc in brain tissue.
The hallmark pathological features of prion diseases include[@budka1995]:
Spongiform change: Intracellular vacuolation (holes) in the neuropil, giving the brain a sponge-like appearance. This represents the most characteristic lesion, though it is not absolutely specific to prion diseases.
Neuronal loss: Progressive disappearance of [neurons](/cell-types/neurons), particularly in cortical and cerebellar regions.
Gliosis: Reactive astrocytosis and microglial activation in affected brain regions.
[prion protein](/proteins/prion-protein) deposition: Abnormal [prion protein](/proteins/prion-protein) accumulation in various patterns - diffuse synaptic deposits, perivacuolar, perineuronal, and plaque-type deposits. The pattern of [prion protein](/proteins/prion-protein) deposition varies by disease subtype and is useful for classification.
Prion diseases share several features with other neurodegenerative disorders characterized by protein misfolding, including [Alzheimer's disease](/diseases/alzheimers-disease) ([amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau)), [Parkinson's disease](/diseases/parkinsons-disease) ([alpha-alpha-synuclein](/proteins/alpha-synuclein))), and [ALS](/diseases/amyotrophic-lateral-sclerosis) ([TDP-43](/proteins/tdp43-protein), [SOD1](/genes/sod1))[@jucker2013]. These "proteinopathies" all involve the accumulation of misfolded proteins in the brain and likely share common pathogenic mechanisms including template-based propagation, spreading through neural circuits, and neurotoxicity.
Importantly, several studies have demonstrated that [prion protein](/proteins/prion-protein) can serve as a receptor for other toxic protein aggregates. For example, [alpha-alpha-synuclein](/proteins/alpha-synuclein)) prions can bind to [prion protein](/proteins/prion-protein) and exert toxic effects in cell culture[@luk2009]. Whether this represents a biologically significant interaction in human disease remains under investigation.
There is currently no cure for prion disease, and all therapeutic approaches remain experimental[@geschwind2015]. The fundamental challenge lies in developing compounds that can: (1) prevent the initial conformational conversion of [prion protein](/proteins/prion-protein)^C to [prion protein](/proteins/prion-protein)^Sc, (2) clear existing [prion protein](/proteins/prion-protein)^Sc deposits, and (3) repair or replace damaged [neurons](/cell-types/neurons).
Several therapeutic strategies have been explored in preclinical and clinical settings:
Antisense oligonucleotides (ASOs): ASOs targeting PRNP mRNA have shown remarkable efficacy in animal models, reducing [prion protein](/proteins/prion-protein) expression and preventing disease progression[@raymond2019]. Clinical trials are underway to evaluate safety and efficacy in human prion disease.
Small molecule inhibitors: Compounds that stabilize the [prion protein](/proteins/prion-protein)^C conformation or interfere with [prion protein](/proteins/prion-protein)^Sc formation have shown promise in cell culture and animal models[@caughey1998]. Examples include quinacrine, pentosan polysulfate, and various polyanionic compounds.
Immunotherapy: Both active immunization (vaccination) and passive immunization (antibody administration) approaches have been explored to generate anti-[prion protein](/proteins/prion-protein) antibodies that could clear prion aggregates[@sigurdsson2004].
Gene therapy: Viral vector-mediated delivery of PRNP-targeting constructs offers a potential approach for long-term suppression of [prion protein](/proteins/prion-protein) expression.
Transgenic mouse models expressing human or bovine [prion protein](/proteins/prion-protein) have been essential for understanding prion disease pathogenesis and testing therapeutic approaches[@carlson1994]. These models recapitulate key features of human disease including clinical signs, neuropathology, and [prion protein](/proteins/prion-protein)^Sc accumulation. The development of knock-in mice expressing wild-type and mutant human PRNP has enabled more accurate modeling of human prion diseases.
Cell culture models, including neural cell lines and primary [neurons](/cell-types/neurons), provide accessible systems for studying [prion propagation](/mechanisms/prion-propagation) and testing therapeutics[@caughey1989]. Cell-free conversion assays using recombinant [prion protein](/proteins/prion-protein) have enabled detailed biochemical studies of the conversion process.
Prion diseases present unique challenges for public health due to their long incubation periods (potentially decades in variant [CJD](/diseases/creutzfeldt-jakob)), the inefficiency of transmission, and the resistance of prions to standard decontamination methods[@who1999]. Strict protocols for sterilization of surgical instruments and screening of blood and tissue donations are essential components of preventive measures.
The identification of vCJD transmission through blood transfusion has raised particular concern, leading to implementation of donor deferral policies in affected countries and ongoing research into prion reduction technologies for blood products[@houston2000].
Research into prion diseases continues to advance on multiple fronts[@collinge2021]. Recent developments have focused on improving understanding of the structural basis for prion strain diversity, the development of sensitive diagnostic assays capable of detecting [prion protein](/proteins/prion-protein)^Sc in peripheral tissues and bodily fluids, and the advancement of therapeutic candidates through clinical trials. The convergence of prion research with broader [neurodegeneration](diseases/neurodegeneration) research holds promise for identifying common therapeutic targets applicable across multiple proteinopathies.
New diagnostic approaches include:
Current clinical trials are evaluating:
Prion diseases represent a unique paradigm in [neurodegeneration](diseases/neurodegeneration), demonstrating that protein misfolding alone can cause infectious disease. While rare in absolute terms, understanding prion pathogenesis has provided fundamental insights into the broader field of [protein aggregation](/mechanisms/protein-aggregation) disorders affecting millions worldwide.
Sporadic [CJD](/diseases/creutzfeldt-jakob)](/diseases/creutzfeldt-jakob) (sCJD) remains the most common human prion disease globally, with an annual incidence of approximately 1-2 cases per million population across all ethnic groups and geographic regions[@masters1979]. This relatively stable incidence rate has been documented consistently across multiple continents, suggesting a uniform spontaneous conversion rate in human populations. The median age of onset for sCJD is approximately 62 years, with a slight male predominance in some population studies.
The epidemiology of variant [CJD](/diseases/creutzfeldt-jakob) (vCJD) demonstrated a striking geographic and temporal pattern, with the United Kingdom experiencing the overwhelming majority of cases during the BSE epidemic of the 1990s and early 2000s[@andrews2007]. Between 1996 and 2011, the United Kingdom reported 177 confirmed cases of vCJD, with additional cases identified in France (27), Ireland (4), Spain (5), Italy (3), and other nations. The overall case fatality rate approaches 100%, as no effective disease-modifying treatments exist.
Genetic prion diseases, including familial [CJD](/diseases/creutzfeldt-jakob), fatal familial insomnia, and Gertsmann-Straussler-Scheinker syndrome, collectively account for approximately 10-15% of all human prion disease cases[@kovacs2021]. These autosomal dominant disorders show characteristic founder effects in certain populations, with notably higher prevalence in families of Libyan Jewish descent (due to the E200K mutation), Slovakian populations (P102L mutation), and Chilean families.
Despite extensive investigation, the precise triggers for sporadic prion disease remain unknown. Several hypotheses have been proposed, including spontaneous conformational conversion of [prion protein](/proteins/prion-protein)^C, somatic mutations in the PRNP gene, and exposure to environmental prions at subclinical levels[@collinge2001a]. The identification of specific risk factors has proven challenging due to the rarity of the disease and the long incubation periods potentially involved.
For acquired prion diseases, the evidence for specific risk factors is clearer. Iatrogenic [CJD](/diseases/creutzfeldt-jakob) has been documented following exposure to contaminated human growth hormone (approximately 200 cases worldwide), dura mater grafts, corneal transplants, and neurosurgical instruments[@brown2001]. The blood transfusion-associated transmission of vCJD represents a particularly concerning pathway, with four documented cases in the United Kingdom, leading to implementation of donor deferral policies.
The central event in prion disease pathogenesis is the conformational conversion of the normal cellular [prion protein](/proteins/prion-protein) ([prion protein](/proteins/prion-protein)^C) to the disease-associated isoform ([prion protein](/proteins/prion-protein)^Sc)[@cohen1998]. This process involves a dramatic structural transformation from a predominantly alpha-helical protein to one rich in beta-sheet structure. The resulting [prion protein](/proteins/prion-protein)^Sc shares the same primary amino acid sequence as [prion protein](/proteins/prion-protein)^C but differs profoundly in its biochemical and biological properties.
The template-directed nature of this conversion means that [prion protein](/proteins/prion-protein)^Sc can induce the misfolding of neighboring [prion protein](/proteins/prion-protein)^C molecules, creating a self-propagating aggregation cycle[@caughey2003a]. This property explains the observed "strain" diversity in prion diseases, as different conformations of [prion protein](/proteins/prion-protein)^Sc can encode distinct biological properties while maintaining the same amino acid sequence.
[prion protein](/proteins/prion-protein)^Sc aggregation proceeds through the formation of oligomeric intermediates, which subsequently assemble into amyloid fibrils characteristic of prion disease neuropathology[@caughey1995]. These fibrils exhibit the tinctorial properties typical of amyloid deposits, staining with Congo red (showing apple-green birefringence) and thioflavin S. The fibrillar structures serve as the template for further recruitment of [prion protein](/proteins/prion-protein)^C, creating a positive feedback loop that drives disease progression.
The kinetics of [prion protein](/proteins/prion-protein)^Sc formation follow a characteristic sigmoidal curve, with an initial lag phase during which oligomeric nuclei form, followed by rapid exponential accumulation as the fibril template catalyzes further conversion[@bessen1994]. This understanding has informed therapeutic strategies aimed at interrupting the aggregation process.
Microglial activation represents a hallmark of prion disease neuropathology, with ramified [microglia](/cell-types/microglia) transforming into amoeboid phagocytes in regions of [prion protein](/proteins/prion-protein)^Sc accumulation[@giese1998]. This activation is driven by recognition of [prion protein](/proteins/prion-protein)^Sc aggregates by pattern recognition receptors, including Toll-like receptors and the NLRP3 inflammasome. The resulting neuroinflammatory response includes production of pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha), reactive oxygen species, and complement proteins.
The role of [neuroinflammation](/mechanisms/neuroinflammation) in prion disease pathogenesis remains incompletely understood. While inflammation likely contributes to neuronal dysfunction and death, studies in microglial-depleted models suggest that microglial responses may also be important for clearance of [prion protein](/proteins/prion-protein)^Sc aggregates[@zhu2016]. This complexity has implications for therapeutic targeting of [neuroinflammation](/mechanisms/neuroinflammation).
Reactive astrocytosis accompanies microglial activation in prion disease, with [astrocytes](/cell-types/astrocytes) proliferating and upregulating glial fibrillary acidic protein ([GFAP](/genes/gfap)](/proteins/gfap)) expression[@moser2006]. Astrocytes may contribute to disease pathogenesis through several mechanisms, including impaired glutamate reuptake leading to excitotoxicity, compromised blood-brain barrier function, and production of pro-inflammatory mediators.
MRI findings in prion disease include characteristic signal abnormalities on diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) sequences[@collie2002]. The most common pattern involves hyperintense signals in the [basal ganglia](/brain-regions/basal-ganglia) (particularly the caudate nucleus and putamen), with cortical involvement also frequently observed. The "cortical ribbon" sign, reflecting cortical hyperintensity, is particularly characteristic of vCJD.
The 14-3-3 protein detection in cerebrospinal fluid has been widely used as a supportive diagnostic marker for [CJD](/diseases/creutzfeldt-jakob), with sensitivity and specificity rates of approximately 94% and 84% respectively[@zerr2021]. However, the 14-3-3 test has limitations, including false positives in other neurological conditions and variable sensitivity across [CJD](/diseases/creutzfeldt-jakob) subtypes.
Neurofilament light chain (NfL) has emerged as a promising biomarker for disease progression and therapeutic monitoring in prion disease[@khalil2022]. Elevated NfL levels in cerebrospinal fluid and plasma reflect ongoing neuronal injury and correlate with disease severity and progression rate.
RT-QuIC technology has revolutionized prion disease diagnosis by enabling detection of [prion protein](/proteins/prion-protein)^Sc with high sensitivity and specificity in cerebrospinal fluid, nasal brushings, and other tissues[@atarashi2011]. This assay uses recursive cycles of incubation and shaking to convert recombinant [prion protein](/proteins/prion-protein) in the presence of patient-derived [prion protein](/proteins/prion-protein)^Sc, producing a fluorescent signal indicative of prion activity. RT-QuIC has become an important tool in the diagnostic workup of suspected prion cases.
The species barrier refers to the reduced efficiency of prion transmission between different species, reflecting the dependency of [prion protein](/proteins/prion-protein)^Sc formation on the amino acid sequence of the substrate [prion protein](/proteins/prion-protein)^C[@race1995]. When prions from one species are inoculated into another, the conformational compatibility between the incoming [prion protein](/proteins/prion-protein)^Sc and the recipient [prion protein](/proteins/prion-protein)^C determines transmission efficiency. This barrier can be complete (no transmission) or partial, resulting in variable incubation periods and disease phenotypes.
Chronic wasting disease (CWD) in cervids represents a growing public health concern due to evidence of prion transmission to other species and the potential for zoonotic transmission to humans[@kong2005]. Experimental studies have demonstrated CWD prion transmission to squirrels, ferrets, and non-human primates, though natural transmission to humans has not been documented. Ongoing surveillance and research remain priorities for public health agencies.
The [prion protein](/proteins/prion-protein) gene (PRNP) contains several polymorphisms that modify disease risk and phenotype in human prion disease[@mead2001]. The common methionine/valine polymorphism at codon 129 profoundly influences susceptibility to sporadic [CJD](/diseases/creutzfeldt-jakob), disease phenotype in variant [CJD](/diseases/creutzfeldt-jakob), and the clinical presentation of genetic prion diseases. Homozygosity at codon 129 (either MM or VV) is associated with increased susceptibility to sporadic [CJD](/diseases/creutzfeldt-jakob).
Beyond PRNP, genome-wide association studies have identified additional genetic loci influencing prion disease susceptibility and phenotype[@mead2012]. These include genes involved in protein homeostasis, lipid metabolism, and immune function. Understanding these genetic modifiers may inform disease prediction and therapeutic targeting.
Transgenic mouse models expressing human PRNP or mutant PRNP variants have been essential for understanding human prion disease pathogenesis[@telling2001]. These models recapitulate key features of human disease, including clinical signs, neuropathology, and [prion protein](/proteins/prion-protein)^Sc accumulation. The development of humanized mouse models expressing wild-type and mutant human [prion protein](/proteins/prion-protein) has enabled more accurate modeling of human prion diseases and testing of therapeutic interventions.
Cell-free conversion assays using recombinant [prion protein](/proteins/prion-protein) substrates have enabled detailed biochemical studies of prion formation and strain properties[@saborio2004]. These systems allow precise control over experimental conditions and have provided fundamental insights into the mechanism of template-directed misfolding. Protein misfolding cyclic amplification (PMCA) extends these capabilities to detect and propagate prions from small amounts of patient tissue.
Antisense oligonucleotides (ASOs) targeting PRNP mRNA represent one of the most promising therapeutic approaches currently in development[@nazor2022]. By reducing expression of the [prion protein](/proteins/prion-protein), ASOs can prevent formation of new [prion protein](/proteins/prion-protein)^Sc and potentially clear existing aggregates. Preclinical studies in mouse models have demonstrated impressive efficacy, with ASO treatment significantly extending survival in prion-infected animals.
Both active immunization (vaccination) and passive immunization (antibody administration) strategies have been explored for prion disease treatment[@polymenidou2005]. Anti-[prion protein](/proteins/prion-protein) antibodies can neutralize circulating [prion protein](/proteins/prion-protein)^Sc and facilitate clearance by the immune system. However, delivery of antibodies to the central nervous system remains a significant challenge, and no immunotherapeutic approach has yet reached clinical trials for prion disease.
Numerous small molecules have been screened for their ability to inhibit [prion protein](/proteins/prion-protein)^Sc formation or promote clearance[@caughey2013]. Compounds that stabilize the [prion protein](/proteins/prion-protein)^C conformation, interfere with protein-protein interactions required for aggregation, or promote cellular clearance pathways have shown activity in cell culture and animal models. However, translation to clinical application has proven challenging due to issues of blood-brain barrier penetration and off-target toxicity.
Viral vector-mediated delivery of PRNP-targeting constructs offers potential for long-term suppression of [prion protein](/proteins/prion-protein) expression[@huang2021]. Adeno-associated virus (AAV) vectors can deliver antisense constructs or RNA interference elements to [neurons](/cell-types/neurons), reducing [prion protein](/proteins/prion-protein)^C expression and preventing disease progression in animal models.
Prions exhibit remarkable resistance to standard sterilization methods, requiring specialized protocols for effective decontamination[@brown1998]. Recommended methods include extended autoclaving at 134°C for 18 minutes or treatment with sodium hydroxide (1N NaOH) or sodium hypochlorite (2% available chlorine). Standard alcohol-based disinfectants and formaldehyde fixation are ineffective against prions.
The identification of variant [CJD](/diseases/creutzfeldt-jakob) transmission through blood transfusion prompted implementation of donor deferral policies in affected countries[@leflere2001]. Individuals who have received a blood transfusion in the United Kingdom, Ireland, or France since 1980 are permanently deferred from donating blood in many countries. Prion reduction technologies for blood products remain under development.